上海淋巴结节 恶性 早期 能治好吗上海肺结节3mm实性结节,上海目前治疗小三阳最好的药,上海甲状腺4a级最佳治疗方案,上海肺结节一般吃什么,上海合肥最著名的老中医,上海肾上腺结节手术恢复时间,上海左乳腺结节病灶3类

SAN FRANCISCO, Sept. 9 (Xinhua) -- AOL's chief executive officer (CEO) Tim Armstrong has reached out to Yahoo for talks of a merger of the two companies, U.S. media reported on Friday.Armstrong is discussing options for a combination aimed at strengthening the two Internet companies, Bloomberg quoted two people who are familiar with the matter as saying.The report said that the AOL CEO had been interested in a merger with Yahoo last year but was rejected while Carol Bartz served as Yahoo CEO, who was ousted by Yahoo's board on Tuesday.Reconsidering the option after Bartz's departure, Armstrong has talked with private equity firms and investment bankers from Allen & Co. working with Yahoo.Under one scenario being considered, Yahoo would acquire AOL and Armstrong would become CEO of the combined company, said the source.Both Yahoo and AOL are suffering from declining revenues, struggling to compete against companies like Google and Facebook. Some analysts said that the merger could not provide a long-term solution to the problems the two companies face after they failed to keep up with Internet trends.

WASHINGTON, June 7 (Xinhua) -- Salmonella infections have not decreased during the past 15 years and have instead increased by 10 percent in recent years in the United States, according to a report released Tuesday by the Centers for Disease Control and Prevention (CDC).During the same time period, illnesses from the serious Shiga toxin-producing E. coli O157 have been cut nearly in half and the overall rates of foodborne infections have been reduced by 23 percent, the new Vital Signs report said.The report summarizes 2010 data from CDC's Foodborne Diseases Active Surveillance Network (FoodNet), which serves as America's report card for food safety by tracking whether nine of the most common infections transmitted through foods are increasing or decreasing."Although foodborne infections have decreased by nearly one-fourth in the past 15 years, more than one million people in this country become ill from Salmonella each year, and Salmonella accounts for about half of the hospitalizations and deaths among the nine foodborne illnesses CDC tracks through FoodNet," said CDC Director Thomas Frieden in a statement.In 2010, FoodNet sites, which include about 15 percent of the American population, reported nearly 20,000 illnesses, 4,200 hospitalizations and 68 deaths from nine foodborne infections. Of those, Salmonella caused more than 8,200 infections, nearly 2,300 hospitalizations and 29 deaths (54 percent of the total hospitalizations and 43 percent of the total deaths reported through FoodNet). CDC estimates that there are 29 infections for every lab-confirmed Salmonella infection.Salmonella, which is responsible for an estimated 365 million U.S. dollars in direct medical costs each year in the United States, can be challenging to address because so many different foods like meats, eggs, produce, and even processed foods, can become contaminated with it and finding the source can be challenging because it can be introduced in many different ways.In response to that challenge, the U.S. Food and Drug Administration, which regulates eggs, produce and many processed foods, has developed new rules for the egg industry to follow under its recently expanded regulatory authorities.The rate of E. coli O157 cases reported by FoodNet was two cases per 100,000 people in 1997 and, by 2010, had decreased to 0.9 cases per 100,000 people. The CDC credits the reduction in E. coli to improved detection and investigation of outbreaks, cleaner slaughter methods, better inspections of ground beef processing plants, and increased awareness by consumers and restaurant employees of the importance of properly cooking beef.

LONDON, Sept. 22 (Xinhua) -- A British publisher on Thursday issued an "unauthorized autobiography" of the founder of the controversial Wikileaks website Julian Assange.Assange became a global figure after he published 250,000 secret United States diplomatic cables on his Wikileaks website, which became a serious embarrassment to the American government.He was then accused by two women of rape when he was in Sweden. Swedish police said they wanted to question him, and issued a European Arrest Warrant in 2010 for him.Assange, 40, denies the allegations and surrendered himself to police in London at the end of 2010, and the Swedish authorities applied for his extradition to face questioning.Assange fought the extradition bid in the English courts, fearing that he could face further extradition from Sweden to the United States where he could face criminal charges related to the publishing of the secret cables, but failed.He appealed against the extradition ruling in July and a final decision on the case will be made by senior English judges, probably before Christmas.Assange agreed to cooperate with Edinburgh-based publisher Canongate in publishing an autobiography and had 50 hours of interviews with a ghostwriter between January and March this year, while he was on bail awaiting an outcome of the extradition hearings.He received a 500,000 pound advance (about 768,000 U.S. dollars) for the book.Publisher's spokesman Liz Sich told Xinhua Thursday, "It's an unauthorized autobiography -- it is his words. He was contracted to write his autobiography in December; a ghostwriter was assigned to it, approved by the publisher and Julian and an intense amount of work was done in the first three months of 2011. The first draft was delivered on schedule at the end of March. After that there was an hiatus and nothing happened; in June Julian decided he wanted to tear up the contract."Assange has opposed publication, but Sich said, "It is very much Julian's words, it is written in the first person. He didn't want it to be published but he was in breach of his contract. He couldn't pay the advance back because he had used it to pay his lawyers."The book is available only in English at the moment, but a Dutch publisher and a Turkish publisher said they would print translations in their languages, and other foreign language editions are also likely.

WELLINGTON, June 7 (Xinhua) -- Scientists in New Zealand have developed a new drug to fight previously untreatable hypoxic cancer tumors, which form in areas of the body starved of oxygen.The researchers at the Auckland University have entered an agreement for the clinical development of CEN-209, which was developed over 10 years of research, said a statement from the university Tuesday.CEN-209 was designed to enhance the effectiveness of radiotherapy and chemotherapy in solid hypoxic tumors, which were resistant to standard cancer therapies, said the statement. In lung cancer patients for example, about half of tumors had hypoxic regions.The new drug worked by damaging the DNA of hypoxic cancer cells, while leaving normal, healthy tissues alone.CEN-209 was designed and created by researchers at the university's Auckland Cancer Society Research Centre (ACSRC), using computer models of drug transport within tumors to accurately predict the anti-tumor activity of the drugs."Our computer models of drug transport developed in-house allowed the synthetic chemists to test their design theories and considerably shortened the discovery process," said Associate Professor Michael Hay, who led the ACSRC research chemists."CEN-209 improves markedly on previous agents in this class in terms of its ability to penetrate tumors, and this is reflected by its improved activity in the laboratory, when combined with long or short courses of radiotherapy," said researcher Professor Bill Wilson.Under the agreement between the university's Auckland UniServices Ltd. and California-based Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc., Centella will have exclusive rights to CEN-209, which it will develop and trial with Cancer Research UK.The work on CEN-209 is the culmination of a program initiated with funding from the U.S. National Cancer Institute, and more recently from the Maurice Wilkins Centre for Biodiscovery. Ongoing preclinical research on CEN-209 and a backup compound was funded by grants from the Auckland Medical Research Foundation, Genesis Oncology Trust and Health Research Council of New Zealand, said the statement.